GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study.

Aleksandra A SzwedoIngvild DalenKenn Freddy PedersenMarta CamachoDavid BäckströmLars ForsgrenCharalampos TzoulisSophie Winder-RhodesGavin HudsonGanqiang LiuClemens R ScherzerRachael A LawsonAlison J YarnallCaroline H Williams-Gray Angus D MacleodCarl E CounsellOle-Bjørn TysnesGuido AlvesAstrid Elisabeth Mork-Janssonnull null

Published in: Movement disorders : official journal of the Movement Disorder Society (2022)

GBA and APOE genotyping could improve the prediction of cognitive decline in PD, which is important to inform the clinical trial selection and potentially to enable personalized treatment © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

cognitive decline
mild cognitive impairment
clinical trial
genome wide
high throughput
open label
phase ii
gene expression
adipose tissue
double blind
metabolic syndrome
combination therapy
genetic diversity
insulin resistance